Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab monotherapy in patients with locally advanced or metastatic hepatocellular carcinoma not amenable to locoregional therapy
2005-000040-85Phase 2Completed
- Sponsor
- Hannover Medical School
- Start
- Jan 2005
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cetuximab in hepatocellular carcinoma (HCC), sponsored by Hannover Medical School. Primary endpoint: Progression-free survival at 6 months. Started Jan 2005; status: completed.
02
Drugs
cetuximab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2005-000040-85.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-000040-85.